GeneralResearch & Publications

Metabolic syndrome: from global epidemiology to individualized medicine

By November 1, 2007September 24th, 2020No Comments


Clinical Pharmacology & Therapeutics

J A Batsis 1 ,
R E Nieto-Martinez,
F Lopez-Jimenez

The metabolic syndrome (MetS) encompasses a constellation of metabolic
abnormalities that are thought to place patients at higher risk for the
development of diabetes and cardiovascular (CV) disease. The underlying
pathophysiology is still a point of contention among various professional
organizations leading to inconsistencies in the manner in which MetS is
defined. Each definition has its advantages and disadvantages. Nonetheless,
there is an agreement that insulin resistance and obesity are likely the
central contributing factors. Because the prevalence of obesity has been
increasing at a frightening rate in the past few decades, MetS represents a
major public health problem that should be identified clinically in
individual patients. This review describes the changing epidemiology of
obesity and of MetS and discusses its importance in CV disease. We outline
the existing controversies that surround MetS and discuss the role of
lifestyle, pharmacological, surgical, and novel approaches in its


Interested in this research and working with us? Please contact us here.